Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer

We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Braun, M S, Adab, F, Bradley, C, McAdam, K, Thomas, G, Wadd, N J, Rea, D, Philips, R, Twelves, C, Bozzino, J, MacMillan, C, Saunders, M P, Counsell, R, Anderson, H, McDonald, A, Stewart, J, Robinson, A, Davies, S, Richards, F J, Seymour, M T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394314/
https://www.ncbi.nlm.nih.gov/pubmed/14520437
http://dx.doi.org/10.1038/sj.bjc.6601237
_version_ 1782155386757840896
author Braun, M S
Adab, F
Bradley, C
McAdam, K
Thomas, G
Wadd, N J
Rea, D
Philips, R
Twelves, C
Bozzino, J
MacMillan, C
Saunders, M P
Counsell, R
Anderson, H
McDonald, A
Stewart, J
Robinson, A
Davies, S
Richards, F J
Seymour, M T
author_facet Braun, M S
Adab, F
Bradley, C
McAdam, K
Thomas, G
Wadd, N J
Rea, D
Philips, R
Twelves, C
Bozzino, J
MacMillan, C
Saunders, M P
Counsell, R
Anderson, H
McDonald, A
Stewart, J
Robinson, A
Davies, S
Richards, F J
Seymour, M T
author_sort Braun, M S
collection PubMed
description We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial.
format Text
id pubmed-2394314
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23943142009-09-10 Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer Braun, M S Adab, F Bradley, C McAdam, K Thomas, G Wadd, N J Rea, D Philips, R Twelves, C Bozzino, J MacMillan, C Saunders, M P Counsell, R Anderson, H McDonald, A Stewart, J Robinson, A Davies, S Richards, F J Seymour, M T Br J Cancer Clinical We previously reported high activity for oxaliplatin and a modified de Gramont regimen (OxMdG) in a single centre study of patients with metastatic colorectal cancer. We now report results with a further 56 patients treated at 14 centres. Low rates of grade 3 and 4 toxicity were seen, with no toxic deaths. Objective response rates were CR/PR=53%; NC=34.7%; PD=12.2%. Median time to progression was 8.3 months and overall survival was 14.5 months. This regimen is more convenient than those based around the conventional de Gramont regimen but is highly active and well tolerated; it forms part of a current UK MRC phase 3 trial. Nature Publishing Group 2003-10-06 2003-09-30 /pmc/articles/PMC2394314/ /pubmed/14520437 http://dx.doi.org/10.1038/sj.bjc.6601237 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Clinical
Braun, M S
Adab, F
Bradley, C
McAdam, K
Thomas, G
Wadd, N J
Rea, D
Philips, R
Twelves, C
Bozzino, J
MacMillan, C
Saunders, M P
Counsell, R
Anderson, H
McDonald, A
Stewart, J
Robinson, A
Davies, S
Richards, F J
Seymour, M T
Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
title Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
title_full Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
title_fullStr Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
title_full_unstemmed Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
title_short Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
title_sort modified de gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer
topic Clinical
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394314/
https://www.ncbi.nlm.nih.gov/pubmed/14520437
http://dx.doi.org/10.1038/sj.bjc.6601237
work_keys_str_mv AT braunms modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT adabf modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT bradleyc modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT mcadamk modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT thomasg modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT waddnj modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT read modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT philipsr modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT twelvesc modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT bozzinoj modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT macmillanc modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT saundersmp modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT counsellr modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT andersonh modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT mcdonalda modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT stewartj modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT robinsona modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT daviess modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT richardsfj modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer
AT seymourmt modifieddegramontwithoxaliplatininthefirstlinetreatmentofadvancedcolorectalcancer

Ejemplares similares